Liana Asatryan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4172187/publications.pdf

Version: 2024-02-01

36 papers	1,045 citations	361413 20 h-index	434195 31 g-index
36 all docs	36 docs citations	36 times ranked	883 citing authors

#	Article	IF	Citations
1	Antibiotic-induced disruption of commensal microbiome linked to increases in binge-like ethanol consumption behavior. Brain Research, 2020, 1747, 147067.	2.2	18
2	A novel pharmacotherapy approach using P-glycoprotein (PGP/ABCB1) efflux inhibitor combined with ivermectin to reduce alcohol drinking and preference in mice. Alcohol, 2020, 86, 1-8.	1.7	5
3	Residues in Transmembrane Segments of the P2X4 Receptor Contribute to Channel Function and Ethanol Sensitivity. International Journal of Molecular Sciences, 2020, 21, 2471.	4.1	6
4	Cross-Talk between P2X and NMDA Receptors. International Journal of Molecular Sciences, 2020, 21, 7187.	4.1	15
5	Dopamine Receptor Blockade Attenuates Purinergic P2X4 Receptor-Mediated Prepulse Inhibition Deficits and Underlying Molecular Mechanisms. Frontiers in Cellular Neuroscience, 2019, 13, 331.	3.7	18
6	Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice. Journal of Visualized Experiments, 2019, , .	0.3	9
7	The Avermectin Family as Potential Therapeutic Compounds for Alcohol Use Disorder: Implications for Using P2X4 Receptor as a Drug-Screening Platform. , 2019, , 661-670.		1
8	P2X7 Receptor Antagonist A804598 Inhibits Inflammation in Brain and Liver in C57BL/6J Mice Exposed to Chronic Ethanol and High Fat Diet. Journal of NeuroImmune Pharmacology, 2019, 14, 263-277.	4.1	20
9	Preclinical evaluation of avermectins as novel therapeutic agents for alcohol use disorders. Psychopharmacology, 2018, 235, 1697-1709.	3.1	16
10	Ethanol differentially modulates P2X4 and P2X7 receptor activity and function in BV2 microglial cells. Neuropharmacology, 2018, 128, 11-21.	4.1	39
11	Reduced expression of purinergic P2X4 receptors increases voluntary ethanol intake in C57BL/6J mice. Alcohol, 2018, 68, 63-70.	1.7	16
12	Similarities in Blood Mononuclear Cell Membrane Phospholipid Profiles During Malignancy. Medical Sciences (Basel, Switzerland), 2018, 6, 105.	2.9	0
13	Preclinical development of moxidectin as a novel therapeutic for alcohol use disorder. Neuropharmacology, 2017, 113, 60-70.	4.1	22
14	Role of purinergic P2X4 receptors in regulating striatal dopamine homeostasis and dependent behaviors. Journal of Neurochemistry, 2016, 139, 134-148.	3.9	39
15	Chronic ethanol exposure combined with high fat diet up-regulates P2X7 receptors that parallels neuroinflammation and neuronal loss in C57BL/6J mice. Journal of Neuroimmunology, 2015, 285, 169-179.	2.3	16
16	Avermectins differentially affect ethanol intake and receptor function: implications for developing new therapeutics for alcohol use disorders. International Journal of Neuropsychopharmacology, 2014, 17, 907-916.	2.1	31
17	Multiday administration of ivermectin is effective in reducing alcohol intake in mice at doses shown to be safe in humans. NeuroReport, 2014, 25, 1018-1023.	1.2	16
18	Contribution of P2X4 Receptors to Ethanol Intake in Male C57BL/6 Mice. Neurochemical Research, 2014, 39, 1127-1139.	3.3	39

#	Article	IF	Citations
19	P2X4 receptors (P2X4Rs) represent a novel target for the development of drugs to prevent and/or treat alcohol use disorders. Frontiers in Neuroscience, 2014, 8, 176.	2.8	55
20	Oral ivermectin treatment significantly reduces ethanol intake in male C57BL/6 mice (658.8). FASEB Journal, 2014, 28, 658.8.	0.5	0
21	Tryptophan 46 is a site for ethanol and ivermectin action in P2X4 receptors. Purinergic Signalling, 2013, 9, 621-632.	2.2	31
22	Pharmacological insights into the role of P2X4 receptors in behavioural regulation: lessons from ivermectin. International Journal of Neuropsychopharmacology, 2013, 16, 1059-1070.	2.1	38
23	Ivermectin reduces alcohol intake and preference in mice. Neuropharmacology, 2012, 63, 190-201.	4.1	62
24	Implication of the Purinergic System in Alcohol Use Disorders. Alcoholism: Clinical and Experimental Research, 2011, 35, 584-594.	2.4	60
25	Ethanol Is a Fast Channel Inhibitor of P2X4 Receptors. Journal of Pharmacology and Experimental Therapeutics, 2011, 337, 171-179.	2.5	47
26	A point mutation in the ectodomainâ€transmembrane 2 interface eliminates the inhibitory effects of ethanol in P2X4 receptors. Journal of Neurochemistry, 2010, 112, 307-317.	3.9	34
27	Ivermectin Antagonizes Ethanol Inhibition in Purinergic P2X4 Receptors. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 720-728.	2.5	59
28	Loop 2 Structure in Glycine and GABAA Receptors Plays a Key Role in Determining Ethanol Sensitivity. Journal of Biological Chemistry, 2009, 284, 27304-27314.	3.4	34
29	LDL protein nitration: Implication for LDL protein unfolding. Archives of Biochemistry and Biophysics, 2008, 479, 1-14.	3.0	39
30	Roles of ectodomain and transmembrane regions in ethanol and agonist action in purinergic P2X2 and P2X3 receptors. Neuropharmacology, 2008, 55, 835-843.	4.1	26
31	Modified LDL activates JNKâ€2 phosphorylation and colocalization with mitochondria. FASEB Journal, 2007, 21, A853.	0.5	0
32	LDL nitration induced protein unfolding. FASEB Journal, 2007, 21, A853.	0.5	0
33	LDL phospholipid hydrolysis produces modified electronegative particles with an unfolded apoB-100 protein. Journal of Lipid Research, 2005, 46, 115-122.	4.2	41
34	Heme and lipid peroxides in hemoglobin-modified low-density lipoprotein mediate cell survival and adaptation to oxidative stress. Blood, 2003, 102, 1732-1739.	1.4	32
35	Oxidative Cross-linking of ApoB100 and Hemoglobin Results in Low Density Lipoprotein Modification in Blood. Journal of Biological Chemistry, 1999, 274, 18916-18924.	3.4	117
36	Low Density Lipoprotein (LDL) Modification: Basic Concepts and Relationship to Atherosclerosis. Blood Purification, 1999, 17, 66-78.	1.8	44